Study Participants Receive Other Care Too: Reading the Co-Treatment Details
Study participants receive other care too — not just the regenerative therapy a study is testing. Most participants also get pain medication, physical therapy, other supplements, or standard treatment during the study period. This is called co-treatment or “concomitant care,” and if a study doesn’t report it clearly, you can’t tell how much of the result actually came from the therapy being studied.
Terms to know before you read a study
- Concomitant care (co-treatment): Any medication, therapy, or intervention a participant receives during a study period, in addition to the treatment being studied.
- Intervention group: The group of participants receiving the treatment being tested.
- Comparator or control group: The group receiving standard care, a placebo, or no treatment, used for comparison.
- Attribution: Connecting a result to its actual cause. When co-treatment isn’t reported, attributing an outcome to a single therapy becomes guesswork.
- Cointervention bias: A distortion in results that happens when one group receives more or different extra care than the other, making the groups no longer a fair comparison.
Why the comparison matters: a study with co-treatment reported vs. one without
Clinical trial reporting standards exist specifically because this gap is common. The CONSORT guidelines — the widely used framework that tells researchers what a trial report needs to include — list concomitant care as its own required reporting item, separate from the therapy being tested.
A well-reported study will tell you, for each group, what other care participants received, and roughly how many participants received it. A poorly reported study will describe only the experimental therapy and stay silent on everything else the participants were doing during the study window.
This distinction is not a minor formatting detail. Reviews of published cardiovascular trials found that co-treatments were inadequately reported in a majority of studies, and that studies with weaker co-treatment reporting tended to show larger treatment effects — meaning the gap in reporting lines up with a gap in reliability. A similar pattern showed up in rheumatology trials, where a large share of studies gave no numbers at all on how many participants were using other medications alongside the one being tested.
In practical terms: a study that names its co-treatments and reports them by group is giving you the information you need to judge the result. A study that stays silent on co-treatment is asking you to take the result on faith.
Your co-treatment worksheet: questions to ask before you trust a result
Use this sequence any time you’re reading about a regenerative medicine study — whether it’s a published paper, a study summary, or a study listing.
- Find the study record. If the study is listed on ClinicalTrials.gov, open the Study Details view. Look at the Study Description and Study Design sections to see how the study is set up.
- Check the Arms and Interventions section. This is where the study lists what each group actually received. If it only names the regenerative therapy and nothing else, that’s a gap — most real-world participants receive some other care too, and its absence from the listing is itself information.
- Look for a co-treatment or “concomitant medications” statement. In a published paper, this usually appears in the Methods or Results section, sometimes in a table listing medications by group. If you can’t find one, treat that as an open question rather than assuming there was none.
- Compare the groups, not just the numbers. If the intervention group received meaningfully more physical therapy, pain management, or other support than the comparator group, the difference in outcomes may reflect that gap in care — not the regenerative therapy itself.
- Check whether the study addresses adverse events or safety. Because most regenerative medicine products used outside of an approved clinical trial are not FDA-licensed, a study record’s safety reporting is worth reading on its own, separately from the outcome claims.
- Note what’s still unclear. If co-treatment isn’t reported, write that down as a specific gap — not as a reason to dismiss the study, but as a limit on what it can tell you.
Where the evidence is uncertain — and what to do next
Co-treatment reporting is a known weak spot across clinical research generally, not just in regenerative medicine — the reviews above cover cardiovascular and rheumatology trials, not regenerative medicine specifically, so this article can’t tell you how common the gap is in regenerative medicine studies in particular. What the evidence does support is the general principle: when a study doesn’t report co-treatment, you should treat its outcome claims as less certain, not disregard them outright.
The U.S. Food and Drug Administration (FDA) has separately noted that most stem cell, umbilical cord blood, amniotic fluid, and exosome products marketed as regenerative medicine are not FDA-licensed or approved, and that inclusion of a product in a study listing does not by itself mean the product is legally marketed or has been proven safe and effective. That’s a separate issue from co-treatment reporting, but it’s worth keeping in view when you’re evaluating any specific regenerative medicine claim.
If you’re weighing a specific regenerative medicine study or offer, a reasonable next step is to bring the study record — and the questions above — to a licensed healthcare provider who can help you interpret what was and wasn’t controlled for. If you believe you’re being offered an unapproved regenerative medicine product outside of a clinical trial with FDA oversight, the FDA can be contacted at ocod@fda.hhs.gov, and adverse effects can be reported through the FDA’s MedWatch program.
This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment recommendations. It does not evaluate or endorse any specific regenerative medicine product, provider, clinic, or clinical trial. Speak with a qualified healthcare provider about any specific treatment decision. This article was prepared independently by the Regenerative Evidence Guide editorial team; no physician, researcher, institution, or clinical program reviewed, endorsed, or contributed to it.
By Regenerative Evidence Guide Editorial Team
Updated September 26, 2026
Sources:
FDA — Important Patient and Consumer Information About Regenerative Medicine Therapies
ClinicalTrials.gov — How to Read a Study Record
CONSORT / EQUATOR Network — 24b. Concomitant Care
Leave a Reply